Preventively, monoclonal antibodies targeting the CGRP peptide (galcanezumab, eptinezumab, and fremanezumab) or canonical receptor (erenumab) have been developed for migraine treatment [168,169,170,171,172,173,174,175,176,177,178], and again all have shown unanimous efficacy without significant side effects or safety concerns. Here, CALCA is linked to migraine disorder.